Chronic myeloid leukemia (CML) is characterized by formation of a BCR-ABL fusion gene, usually as a consequence of the Philadelphia (Ph) translocation between chromosomes 9 and 22. Recently the development of new fluorescence in-situ hybridization (FISH) techniques has allowed identification of unexpected deletions of the reciprocal translocation product, the derivative chromosome 9, in 10% to 15% of patients with CML. These deletions are large, span the translocation breakpoint, and occur at the same time as the Ph translocation. Such deletions therefore give rise to previously unsuspected molecular heterogeneity from the very beginning of this disease, and there is mounting evidence for similar deletions associated with other translocations. Several studies have demonstrated that CML patients who carry derivative chromosome 9 deletions exhibit a more rapid progression to blast crisis and a shorter survival. Deletion status is independent of, and more powerful than, the Sokal and Hasford/European prognostic scoring systems. The poor prognosis associated with deletions is seen in patients treated with hydroxyurea or interferon, and preliminary evidence suggests that patients with deletions may also have a worse outcome than nondeleted patients following stem cell transplantation or treatment with imatinib. Poor outcome cannot be attributed to loss of the reciprocal ABL-BCR fusion gene expression alone, and is likely to reflect loss of one or more critical genes within the deleted region. The molecular heterogeneity associated with the Philadelphia translocation provides a new paradigm with potential relevance to all malignancies associated with reciprocal chromosomal translocations and/or fusion gene formation.
Chronic myeloid leukemia ( CML ) is characterized by formation of a BCR - ABL fusion gene , usually as a consequence of the Philadelphia ( Ph ) translocation between chromosomes 9 and 22 . Recently the development of new fluorescence in - situ hybridization ( FISH ) techniques has allowed identification of unexpected deletions of the reciprocal translocation product , the derivative chromosome 9 , in 10 % to 15 % of patients with CML . These deletions are large , span the translocation breakpoint , and occur at the same time as the Ph translocation . Such deletions therefore give rise to previously unsuspected molecular heterogeneity from the very beginning of this disease , and there is mounting evidence for similar deletions associated with other translocations . Several studies have demonstrated that CML patients who carry derivative chromosome 9 deletions exhibit a more rapid progression to blast crisis and a shorter survival . Deletion status is independent of , and more powerful than , the Sokal and Hasford / European prognostic scoring systems . The poor prognosis associated with deletions is seen in patients treated with hydroxyurea or interferon , and preliminary evidence suggests that patients with deletions may also have a worse outcome than nondeleted patients following stem cell transplantation or treatment with imatinib . Poor outcome can not be attributed to loss of the reciprocal ABL - BCR fusion gene expression alone , and is likely to reflect loss of one or more critical genes within the deleted region . The molecular heterogeneity associated with the Philadelphia translocation provides a new paradigm with potential relevance to all malignancies associated with reciprocal chromosomal translocations and/or fusion gene formation .
Which gene fusion is the result of the "philadelphia translocation" or the "philadelphia chromosome" mutation?
Which gene fusion is the result of the " philadelphia translocation " or the " philadelphia chromosome " mutation ?
ABL/BCR fusion
The BCR/ABL gene fusion ABL/BCR fusion